Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
Related Questions
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
How do you approach a patient with a solitary brain metastasis from small cell lung cancer s/p resection with otherwise limited thoracic disease?
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
How do you define treatment volumes for patients treated with neoadjuvant chemoimmunotherapy for resectable NSCLC who are no longer surgical candidates or decline surgery?
What ipsilateral lung constraints if any do you utilize for SBRT and or hypofractionated RT in the lungs?
How do you treat Stage IIIC T4N3 NSCLC?
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
For ultracentral lung cancer abutting the heart, what dose constraints would you use for the heart and bronchus if using 10 fraction ultrahypofractionation?
